Clinical Trial Update: Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects [Phase 2]

View source ↗

Summary

The Phase 2 study evaluating sex differences in the acute effects of PL-3994 in heart failure with preserved ejection fraction has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• PL-3994

Snippet

Sponsor: Palatin Technologies, Inc | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 2 | Status: TERMINATED